GIGerald Illerhaus

Gerald Illerhaus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gerald Illerhaus has a total of 63 co-authors. Here are the top co-authors by number of shared publications:

  • J. Finke

    Department of Hematology/Oncology, Freiburg University Medical Center, Freiburg, Germany

    5 shared publications
  • B. Kasenda

    Department of Hematology/Oncology, Freiburg University Medical Center, Freiburg, Germany

    3 shared publications
  • K. Fritsch

    Department of Hematology/Oncology, Freiburg University Medical Center, Freiburg, Germany

    3 shared publications
  • E. Schorb

    Department of Hematology/Oncology, Freiburg University Medical Center, Freiburg, Germany

    2 shared publications
  • A. Korfel

    Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin

    1 shared publication
  • A. Morgner

    Department of Medicine III, Klinikum Chemnitz GmbH, Chemnitz, Germany

    1 shared publication

Latest Publications

  • Open Access

    Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma

    by Catharina Ruf, Oliver Thomusch, Matthias Goos, Frank Makowiec, Gerald Illerhaus, Guenther Ruf

    In a retrospective study we analyzed the impact of neoadjuvant chemotherapy (CTx) with the PELF - protocol (Cisplatin, Epirubicin, Leukovorin, 5-Fluoruracil) on mortality, recurrence and prognosis of patients with advanced gastric carcinoma, UICC stages Ib-III.


  • Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation

    by E. Schorb, B. Kasenda, J. Atta, S. Kaun, A. Morgner, G. Hess, T. Elter, N. von Bubnoff, M. Dreyling, M. Ringhoffer, et al.

    High-dose chemotherapy followed by autologous stem cell transplantation has been shown to be feasible and highly effective in newly diagnosed primary central nervous system lymphoma. In this retrospective multicenter study, we investigated prognosis and baseline risk factors in patients with primary central nervous system lymphoma who underwent this treatment approach. We retrospectively analyzed 105 immunocompetent patients with primary central nervous system lymphoma who underwent high-dose chemotherapy followed by autologous stem cell transplantation with or without whole brain radiotherapy as first-line consolidation treated at 12 German centers between 1997 and 2011. We estimated survival rates and investigated the impact of age, performance status, serum lactate dehydrogenase level, and deep brain involvement on overall and progression-free survival. Patients were additionally categorized into three prognostic groups according to the Memorial Sloan Kettering Cancer Center prognostic model. After a median follow up of 47 months, median progression-free survival and overall survival was reached after 85 and 121 months; 2- and 5-year survival rates were 82% and 79%, respectively. The Memorial Sloan Kettering Cancer Center prognostic model did not predict survival. Only age revealed some evidence of prognostic relevance. Overall response rate was 95%; of those patients with progressive disease before high-dose chemotherapy, 7 of 20 achieved ongoing complete remission after therapy without whole brain radiation therapy. Transplantation-associated mortality was 2.8%. High-dose chemotherapy followed by autologous stem cell transplantation is a highly effective and safe treatment modality for selected primary central nervous system lymphoma patients. Superiority compared to standard chemotherapy still warrants further investigation.


  • Open Access

    Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature

    by Alexander Stein, Gabriel Glockzin, Andreas Wienke, Dirk Arnold, Thomas Edelmann, Bert Hildebrandt, Stephan Hollerbach, Gerald Illerhaus, Alfred Königsrainer, Michael Richter, et al.

    Background: More than half of patients with colorectal cancer will develop metastatic disease either evident at the time of initial diagnosis or during their course of disease. Besides multidisciplinary management further treatment intensification is warranted to improve the still limited prognosis. Methods/design: In these two multi-centre, randomized phase II trials, conducted in Germany, 380 patients with R0-resectable colorectal liver metastases (PERIMAX) and with unresectable, metastatic colorectal cancer (CHARTA) will be recruited. Patients previously untreated for metastatic disease with either synchronous or metachronous metastases are randomly assigned in a 1:1 ratio to resection of colorectal liver metastases followed by postoperative FOLFOX for 6 months or perioperative FOLFOXIRI and bevacizumab for 3 months pre- and postoperative and resection (PERIMAX), or to induction chemotherapy with FOLFOX and bevacizumab +/− irinotecan for a maximum of 6 months followed by maintenance treatment with fluoropyrimidine and bevacizumab. The primary objective of these trials is to evaluate the feasibility and efficacy of FOLFOXIRI and bevacizumab in metastatic colorectal cancer. Primary endpoint is failure free survival rate at 18 months in the PERIMAX trial and progression free survival rate at 9 months in CHARTA. Secondary objectives include efficacy, safety and tolerability. Discussion: The CHARTA and PERIMAX trials are designed to evaluate the benefits and limitations of a highly active four-drug regimen in distinct treatment situations of metastatic CRC. Eligible patients are classified into resectable liver metastases to be randomized to perioperative treatment with FOLFOXIRI and bevacizumab or postoperative FOLFOX in the PERIMAX, or unresectable metastatic CRC to be randomized between FOLFOX and bevacizumab with or without irinotecan, stratified for clinical groups according to disease and patients’ characteristics in the CHARTA trial. Trial registration: Clinical trial identifier CHARTA: NCT01321957, PERIMAX: NCT01540435


  • Open Access

    Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma—a long-term follow-up study

    by B. Kasenda, E. Schorb, K. Fritsch, J. Finke, G. Illerhaus

    High-dose chemotherapy followed by autologous stem-cell transplantation (HCT–ASCT) is a promising approach in eligible patients with primary central nervous system lymphoma (PCNSL). We report long-term data of patients who were treated according to HCT–ASCT containing protocols. We analyzed survival and relapse rates in 43 (N = 34), 5-year OS and EFS was 82% and 79%, respectively. HCT–ASCT associated related mortality was not observed. Sequential high-dose MTX containing chemotherapy followed by high-dose carmustine/thiotepa plus ASCT (±whole brain irradiation) is safe and leads to high survival rates in eligible patients with newly diagnosed PCNSL.


  • The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients

    by Benjamin Kasenda, Marcel Rehberg, Petra Thürmann, Melanie Franzem, Hendrik Veelken, Kristina Fritsch, Elisabeth Schorb, Jürgen Finke, Dirk Lebiedz, Gerald Illerhaus

    Studies on pharmacokinetics and pharmacodynamics of high-dose methotrexate chemotherapy (HD-MTX) in elderly primary central nervous system lymphoma (PCNSL) patients are rare. MTX exposure time has recently been proposed as an outcome determining factor in PCNSL. We investigated 49 immunocompetent PCNSL patients (female N = 30, male N = 19, median age 73 years) who were treated according to HD-MTX-based protocols. A two-compartment pharmacokinetic model was used to describe the MTX clearance. Response to treatment was assessed by MRI. We used multivariable models to investigate the association between MTX exposure and tumor response as well as survival. Dose normalized MTX peak serum levels [C max, μmol/L g] and dose normalized area under the curve [AUCdn, μmol h/L g] were higher in females than in males, respectively [59.4 (f) vs. 48.1 (m), P < 0.001; 373.2 (f) vs. 271.9 (m), P = 0.008]. Increasing AUC was inversely correlated with tumor response. AUC values above 2,126 h μmol/L were independently associated with shorter overall and progression-free survival [hazard ratio (HR), 4.56, 95 % CI 1.74–11.94; HR 2.87, 95 % CI 1.18–7.00]. Exceedingly high MTX AUC levels can have a negative impact on progression-free and overall survivals in elderly PCNSL patients.


  • Open Access

    Multifocal gastric gastrointestinal stromal tumors (GISTs) with lymph node metastases in children and young adults: A comparative clinical and histomorphological study of three cases including a new case of Carney triad

    by Claudia Otto, Abbas Agaimy, Alexander Braun, Jochen Rädecke, Jens Hoeppner, Gerald Illerhaus, Martin Werner, Udo Kontny, Florian Haller

    Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal tumors of the gastrointestinal tract usually occurring in the 6th to 7th decade of life, while their occurrence in children is rare (1-2%).


  • Therapie von primären zerebralen Lymphomen

    by G. Illerhaus, J. Finke, A. Korfel, U. Schlegel

  • Open Access

    Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly

    by K. Fritsch, B. Kasenda, C. Hader, G. Nikkhah, M. Prinz, V. Haug, S. Haug, G. Ihorst, J. Finke, G. Illerhaus

    Background: Primary central nervous system lymphoma (PCNSL) is an aggressive extranodal non-Hodgkin lymphoma confined to the central nervous system. In this article, we report the results of a pilot trial adding rituximab to the established regimen consisting of methotrexate, procarbazine, and lomustine (R-MCP). Design and methods: PCNSL patients ≥65 years without Karnofsky performance score (KPS) limit were included. R-MCP regimen consisted of rituximab (375 mg/m2 i.v. on days −6, 1, 15, and 29), methotrexate (3 g/m2 i.v., days 2, 16, and 30) followed by folinic rescue, procarbazine (60 mg/m2 orally, days 2–11), and lomustine (110 mg/m2 orally, day 2). A maximum of three 43-day cycles were applied. Primary end point was response to treatment obtained by magnetic resonance imaging. Secondary end points were overall survival (OS) and progression-free survival (PFS). Results: Twenty-eight patients were included (median age 75, median KPS 60%). Best documented response: complete remission in 18 of 28 (64%), partial remission in 5 of 28 (18%), stable disease in 1 of 28 (4%), and progressive disease in 2 of 28 (7%) patients. Response was not assessed in two patients. Two treatment-associated deaths were observed. After a median follow-up of 36 months, the 3-year PFS and OS was 31%. Conclusion: R-MCP regimen is well tolerated and active in elderly patients with newly diagnosed PCNSL.


  • High-Dose Chemotherapy and Stem Cell Transplantation for Primary CNS Lymphoma

    by Carole Soussain, Patrick Johnston, Gerald Illerhaus